loading...| Preferred Name | Hepatocellular Carcinoma | |
| Synonyms |
CellType: hepatocyte PathwayType: signaling Link: https://mammal-profservices.pathwaystudio.com/app/sd?urn=urn:agi-pathway:uuid-7bfe358f-42c1-477f-b4b7-f6ef12486abd CellType: cancer cell PMID: 22652888 PMID: 22212931 Tissue: epithelium PMID: 20175032 NodeType: Pathway Organ: liver Organ_System: digestive system Description: Hepatocellular carcinoma (HCC) is one of the most lethal cancers worldwide. Pathway is built manually using published studies. PMID: 20953207 Pathway_Author: M. Zharkova ORCID:0000-0001-8706-9411 PMID: 23426905 Source: Diseases Notes: Headnote: Hepatocellular carcinoma (HCC) is one of the most lethal cancers worldwide, and is most prevalent in Asia and Africa. In Asia, HCC is commonly related to hepatitis B or C virus (HBV and HCV) infection, while in Africa it is linked to chronic hepatitis B. The incidence is on the rise in some developed countries including Japan, UK, France, and U.S. In more than 80% of cases, HCC is associated with cirrhosis or advanced fibrosis. Cirrhosis typically results from chronic infection with HBV or HCV, alcohol abuse, or metabolic disorders such as hemochromatosis. Less common causes of HCC are exposure to dietary hepatocarcinogen like aflatoxin, insulin resistance syndrome, several genetic disorders, and drug-induced (e.g. anabolic steroids). HCC has a poor prognosis since less than 30% of newly diagnosed patients will be eligible for potential curative treatment. Signaling description: Genetic changes and their biological consequences in human HCC can be divided into several groups including mutation in tumor suppressor genes (TP53, RB1, PTEN, and RUNX3), mutation in oncogenes (MYC, KRAS, HRAS, and BRAF), activation of developmental pathways (WNT/CTNNB1 and NOTCH), and growth factors and their receptors (EGFRs, VEGFRs, IGF1R, TGFBR1, and MET). Outcome effects: The genetic alterations associated with HCC cause block of apoptosis, disruption of cell cycle and differentiation, redundant proliferation and migration of hepatocytes, block of chromatin remodeling and DNA repair, and vascularization. Highlighted proteins: Proteins with increased expression or activity are highlighted in red, and proteins with decreased expression or activity are highlighted in blue. Mutated genes: Mutated gene is shown in white-out style. |
|
| ID |
urn:agi-pathway:uuid-7bfe358f-42c1-477f-b4b7-f6ef12486abd |
|
| database_cross_reference |
PS:PathwayType PS:Description PS:Tissue PS:Pathway_Author PS:Link PS:CellType PS:Organ_System PS:PMID PS:NodeType PS:Notes PS:Organ PS:Source |
|
| has_exact_synonym |
CellType: hepatocyte PathwayType: signaling CellType: cancer cell PMID: 22652888 PMID: 22212931 Tissue: epithelium PMID: 20175032 NodeType: Pathway Organ: liver Organ_System: digestive system Description: Hepatocellular carcinoma (HCC) is one of the most lethal cancers worldwide. Pathway is built manually using published studies. PMID: 20953207 Pathway_Author: M. Zharkova ORCID:0000-0001-8706-9411 PMID: 23426905 Source: Diseases Notes: Headnote: Hepatocellular carcinoma (HCC) is one of the most lethal cancers worldwide, and is most prevalent in Asia and Africa. In Asia, HCC is commonly related to hepatitis B or C virus (HBV and HCV) infection, while in Africa it is linked to chronic hepatitis B. The incidence is on the rise in some developed countries including Japan, UK, France, and U.S. In more than 80% of cases, HCC is associated with cirrhosis or advanced fibrosis. Cirrhosis typically results from chronic infection with HBV or HCV, alcohol abuse, or metabolic disorders such as hemochromatosis. Less common causes of HCC are exposure to dietary hepatocarcinogen like aflatoxin, insulin resistance syndrome, several genetic disorders, and drug-induced (e.g. anabolic steroids). HCC has a poor prognosis since less than 30% of newly diagnosed patients will be eligible for potential curative treatment. Signaling description: Genetic changes and their biological consequences in human HCC can be divided into several groups including mutation in tumor suppressor genes (TP53, RB1, PTEN, and RUNX3), mutation in oncogenes (MYC, KRAS, HRAS, and BRAF), activation of developmental pathways (WNT/CTNNB1 and NOTCH), and growth factors and their receptors (EGFRs, VEGFRs, IGF1R, TGFBR1, and MET). Outcome effects: The genetic alterations associated with HCC cause block of apoptosis, disruption of cell cycle and differentiation, redundant proliferation and migration of hepatocytes, block of chromatin remodeling and DNA repair, and vascularization. Highlighted proteins: Proteins with increased expression or activity are highlighted in red, and proteins with decreased expression or activity are highlighted in blue. Mutated genes: Mutated gene is shown in white-out style. |
|
| id |
urn:agi-pathway:uuid-7bfe358f-42c1-477f-b4b7-f6ef12486abd |
|
| label |
Hepatocellular Carcinoma |
|
| notation |
uuid-7bfe358f-42c1-477f-b4b7-f6ef12486abd |
|
| prefLabel |
Hepatocellular Carcinoma |
|
| treeView |
urn:agi-folder:digestive_system urn:agi-folder:hepatocellular_carcinoma urn:agi-folder:h urn:agi-folder:epithelium |
|
| subClassOf |
urn:agi-folder:digestive_system urn:agi-folder:hepatocellular_carcinoma urn:agi-folder:h urn:agi-folder:epithelium |